Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC5712844/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC5712844/. The analysis below is for the second page.

Title[redir]:
Non-small-cell lung cancers: a heterogeneous set of diseases - PMC
Description:
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have diverse pathological features. During the past decade, in-depth analyses of lung cancer genomes and signalling pathways have further defined NSCLCs as a group of ...

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 6,398,976 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Ncbi.nlm.nih.gov might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

doi, lung, cancer, cells, pubmed, google, scholar, cell, pmc, article, free, tumour, tumours, mutations, nature, stem, nsclc, patients, treatment, egfr, kinase, growth, res, clinical, adc, expression, kras, receptor, scc, origin, factor, inhibitors, resistance, genetic, squamous, oncogenic, immune, including, human, mouse, study, med, target, studies, adenocarcinoma, gemms, potential, microenvironment, response, fgfr,

Topics {✒️}

pro-apoptotic bcl-2-homology domain mutation-based decision-making procedures anti-cd47 antibody-mediated phagocytosis platelet-derived growth factor k-ras oncogene-driven nf-κb inhibitor iκbα pi3k catalytic subunit-α pmc beta search lineage-restricted cre alleles anti-pd-l1 antibody long-standing hypothesis proposes bmp4-nfatc1-thrombospondin-1 axis mucus-producing goblet cells selective pan-fgfr inhibitor intra nasal adenovirus-cre neutrophil elastase-mediated degradation calcitonin gene-related peptide dysfunctional keap1-nrf2 interaction mutant-selective covalent inhibitor urethane-induced lung carcinogenesis cancer-related deaths worldwide1 oncogenic ras-induced secretion small-cell lung cancers keratin-driven cre alleles yap/taz activity contribute fluorescence-activated cell sorting lymphocyte antigen 6g-expressing kinase-dead ikkα knock kras-induced lung adenocarcinoma small-cell lung cancer small-cell lung cancer small-cell lung cancer myeloid-derived suppressor cells modulating epithelial–mesenchymal transition adeno-cre intranasal instillation egfr-driven lung tumors immune-checkpoint molecule pdl1 forkhead box p3-expressing cell-type-specific promoters cell-type specific promoters kinase subunit-α nuclear factor-κb high-throughput analytical approaches overcomes t790m-mediated resistance comparable adc-initiating activity elevated pd-l1 expression oncogenic k-ras neurotrophic tyrosine kinase kras-mutant lung cancer address human–murine differences

Questions {❓}

  • Can knowledge of the cell of origin predict environmental influences that can be targeted for antitumour therapy?
  • Scientists and physicians have better tools than ever to pursue answers to two provocative questions: first, how can we define the specific subsets of NSCLC that differ by cellular and molecular composition?
  • Similar to KRAS mutations, many newly identified potential pro-cancerous changes, such as overexpression of the transcription factors SOX2 and MYC103–105, present clear challenges to our current ideas about treatment approaches — in cases in which there is no clear druggable target, what can be done?
  • The CpG island methylator phenotype: what’s in a name?
  • These mechanisms have not been defined in detail, and there are other important questions to consider: does each genetic subset of NSCLC have its own unique microenvironmental influences, or can common characteristics of how the surroundings drive tumour subsets be uncovered?

Social Networks {👍}(6)

External Links {🔗}(361)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • jQuery
  • jQuery module (jquery-3.6.0)

Emails and Hosting {✉️}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {📦}

  • Ncbi

4.48s.